LYSOGENE   Report issue

For profit Phase 2 Phase 3
Founded: Paris France (2009)

Organization Overview

First Clinical Trial
2011
NCT01474343
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

LYSOGENE

Active Ingredients

Drugs in Phase 3 Trials (1)

lys-saf302 (1 trial)

Drugs in Phase 2 Trials (2)

lys-gm101 (1 trial)

saf-301 (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Gangliosidoses (Phase 2)

Gangliosidosis, GM1 (Phase 2)

Mucopolysaccharidoses (Phase 3)

Mucopolysaccharidosis III (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 3